These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10932837)

  • 1. HAART and adherence.
    Boyle BA
    AIDS Read; 2000 Jul; 10(7):392-6. PubMed ID: 10932837
    [No Abstract]   [Full Text] [Related]  

  • 2. Adherence to highly active antiretroviral therapy (HAAT) at a Federal Medical Centre.
    Shaahu VN; Lawoyin TO; Sangowawa AO
    Afr J Med Med Sci; 2008 Mar; 37(1):29-36. PubMed ID: 18756852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kaposi's sarcoma in a nonadherent HAART patient.
    Ball SC
    AIDS Read; 1999; 9(3):170, 173-4. PubMed ID: 12728902
    [No Abstract]   [Full Text] [Related]  

  • 4. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice.
    Stone VE
    Clin Infect Dis; 2001 Sep; 33(6):865-72. PubMed ID: 11512092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordant responses to HAART in HIV-1 patients: the need to focus on intervention.
    De Maria A
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):523-7. PubMed ID: 17678414
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiretroviral treatment adherence and its correlates in Addis Ababa, Ethiopia.
    Tadios Y; Davey G
    Ethiop Med J; 2006 Jul; 44(3):237-44. PubMed ID: 17447389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [No standard: drug holidays in HAART. Continuous or interval treatment?].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():81. PubMed ID: 15011601
    [No Abstract]   [Full Text] [Related]  

  • 8. Improving adherence to HAART.
    Stone VE; Smith KY
    J Natl Med Assoc; 2004 Feb; 96(2 Suppl):27S-29S. PubMed ID: 14977296
    [No Abstract]   [Full Text] [Related]  

  • 9. Epstein-Barr virus-associated central nervous system lymphoproliferative disease in a patient with acquired immunodeficiency syndrome responsive to highly active antiretroviral therapy.
    Kuo DZ; Milstone AM; Omokaro SO; Friedman AD; Karanjawala ZE; Borowitz M; Joyner ML; Halsey NA; Sibinga EM
    Clin Infect Dis; 2008 May; 46(9):1476-8. PubMed ID: 18419459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges of adherence management in human immunodeficiency virus pharmacotherapy.
    Park-Wyllie LY; Phillips EJ
    Can J Clin Pharmacol; 2003; 10(4):189-95. PubMed ID: 14712324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark.
    Bracher L; Valerius NH; Rosenfeldt V; Herlin T; Fisker N; Nielsen H; Obel N
    Scand J Infect Dis; 2007; 39(9):799-804. PubMed ID: 17701719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.
    Antinori A; Larussa D; Cingolani A; Lorenzini P; Bossolasco S; Finazzi MG; Bongiovanni M; Guaraldi G; Grisetti S; Vigo B; Gigli B; Mariano A; Dalle Nogare ER; De Marco M; Moretti F; Corsi P; Abrescia N; Rellecati P; Castagna A; Mussini C; Ammassari A; Cinque P; d'Arminio Monforte A;
    Clin Infect Dis; 2004 Dec; 39(11):1681-91. PubMed ID: 15578371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 drug resistance among untreated patients in India: Current status.
    Pachamuthu B; Shanmugam S; Nagalingeswaran K; Solomon SS; Solomon S; Solomon S
    J Postgrad Med; 2006; 52(3):183-6. PubMed ID: 16855318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune restoration disorders following HAART.
    Davaro RE; Himlan PH
    AIDS Read; 1999; 9(3):167-9. PubMed ID: 12728901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HIV associated encephalopathy after highly active antiretroviral therapy (HAART)].
    Kishida S
    No To Shinkei; 2004 Apr; 56(4):301-10. PubMed ID: 15237721
    [No Abstract]   [Full Text] [Related]  

  • 16. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System?
    Borrell C; Rodríguez-Sanz M; Pasarín MI; Brugal MT; García-de-Olalla P; Marí-Dell'Olmo M; Caylà J
    Eur J Public Health; 2006 Dec; 16(6):601-8. PubMed ID: 16698886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to highly active antiretroviral therapy.
    Zuger A
    AIDS Clin Care; 1997 Nov; 9(11):86-7. PubMed ID: 11364775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvaging HAART.
    Laurence J
    AIDS Read; 1999 Jul; 9(4):234-5. PubMed ID: 12737111
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.